Pancreatic cancer patients with BRCA1/2 mutations, associated with increased genomic instability, are known to respond more favorably to therapy regimens involving gemcitabine38; thus, our result that nuclear variation is associated with genomic instability may explain this recent finding. The gene discussed is BRCA1; the disease is pancreatic neoplasm.